Literature DB >> 8882137

Grouped caging predisposes male mice to ankylosing enthesopathy.

S Weinreich1, J Capkova, B Hoebe-Hewryk, C Boog, P Ivanyi.   

Abstract

OBJECTIVE: To evaluate the number of males per cage as a possible risk factor for murine ankylosing enthesopathy (ANKENT)--a spontaneous joint disease with parallels to human seronegative spondylarthropathies--since ANKENT shows incomplete penetrance of genetic susceptibility factors among individuals living in a stable environment.
METHODS: Frequency of ANKENT was compared among males housed with females, with other males, or alone.
RESULTS: In three independent cohorts, a trend was observed that males housed with females rarely develop the disease, in contrast to males housed with other males (P < 0.25, P < 0.05, and P < 0.01). Furthermore, no males caged alone developed ANKENT, whereas disease did occur in males grouped together (P < 0.01). When healthy males (retired breeders) were recaged either alone or with other males, ANKENT developed among the grouped males only (P < 0.005).
CONCLUSIONS: Caging males together is a relative risk factor for ANKENT. Grouped caging may perturb the immune system through endocrine pathways or modify microbiological load through behaviour (for example, infection due to biting).

Entities:  

Mesh:

Year:  1996        PMID: 8882137      PMCID: PMC1010263          DOI: 10.1136/ard.55.9.645

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  5 in total

1.  A computer program for comparing K samples with right-censored data.

Authors:  E T Lee; M M Desu
Journal:  Comput Programs Biomed       Date:  1972-11

2.  Genetic, hormonal and behavioural influence on spontaneously developing arthritis in normal mice.

Authors:  R Holmdahl; L Jansson; M Andersson; R Jonsson
Journal:  Clin Exp Immunol       Date:  1992-06       Impact factor: 4.330

3.  Germ-line transmission of a disrupted beta 2-microglobulin gene produced by homologous recombination in embryonic stem cells.

Authors:  M Zijlstra; E Li; F Sajjadi; S Subramani; R Jaenisch
Journal:  Nature       Date:  1989-11-23       Impact factor: 49.962

4.  Maternal age influences risk for HLA-B27 associated ankylosing enthesopathy in transgenic mice.

Authors:  S Weinreich; B Hoebe; P Ivanyi
Journal:  Ann Rheum Dis       Date:  1995-09       Impact factor: 19.103

5.  HLA-B27 as a relative risk factor in ankylosing enthesopathy in transgenic mice.

Authors:  S Weinreich; F Eulderink; J Capkova; M Pla; K Gaede; J Heesemann; L van Alphen; C Zurcher; B Hoebe-Hewryk; F Kievits
Journal:  Hum Immunol       Date:  1995-02       Impact factor: 2.850

  5 in total
  5 in total

1.  Sexual dimorphism, but not testosterone itself, is responsible for ankylosing enthesitis of the ankle in B10.BR (H-2k) male mice.

Authors:  J Capkova; P Ivanyi; Z Rehakova
Journal:  Ann Rheum Dis       Date:  2006-01       Impact factor: 19.103

2.  Genetic characterisation of spontaneous ankylosing arthropathy with unique inheritance from Fas-deficient strains of mice.

Authors:  S Mori; M-C Zhang; N Tanda; F Date; M Nose; H Furukawa; M Ono
Journal:  Ann Rheum Dis       Date:  2006-03-28       Impact factor: 19.103

3.  Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis.

Authors:  Rik J U Lories; Inge Derese; Frank P Luyten
Journal:  J Clin Invest       Date:  2005-05-12       Impact factor: 14.808

4.  Lipopolysaccharide treatment suppresses spontaneously developing ankylosing enthesopathy in B10.BR male mice: the potential role of interleukin-10.

Authors:  Jana Capkova; Tomas Hrncir; Alena Kubatova; Helena Tlaskalova-Hogenova
Journal:  BMC Musculoskelet Disord       Date:  2012-06-21       Impact factor: 2.362

5.  The effect of anti-IL-6 receptor antibody for the treatment of McH-lpr/lpr-RA1 mice that spontaneously developed destructive arthritis and enthesitis.

Authors:  Takuya Izumiyama; Yu Mori; Shiro Mori; Naoko Mori; Tetsuya Kodama; Eiji Itoi
Journal:  BMC Musculoskelet Disord       Date:  2019-06-15       Impact factor: 2.362

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.